Compounds > mibefradil
Page last updated: 2024-08-24

mibefradil and Brain Neoplasms

mibefradil has been researched along with Brain Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X1
Gray, L; Krouse, AJ; Macdonald, T; McCray, J1
Bigner, DD; Friedman, HS; Gray, LA; Keir, ST; Reardon, DA1
Kowalski, L; Popp, B; Schlesinger, D; Sheehan, JP; Xu, Z1
Augustin, E; Brautigan, DL; Dziegielewska, B; Dziegielewski, J; Gray, LS; Hosing, AS; Larner, JM; Valerie, NC1

Trials

1 trial(s) available for mibefradil and Brain Neoplasms

ArticleYear
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
    Neuro-oncology, 2017, 06-01, Volume: 19, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Calcium Channels, T-Type; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Mibefradil; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Young Adult

2017

Other Studies

4 other study(ies) available for mibefradil and Brain Neoplasms

ArticleYear
Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study.
    Assay and drug development technologies, 2015, Volume: 13, Issue:10

    Topics: Antihypertensive Agents; Brain Neoplasms; Calcium Channel Blockers; Calcium Channels, T-Type; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Repositioning; Drug Synergism; Humans; Mibefradil; Neoplasms

2015
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
    Journal of neuro-oncology, 2013, Volume: 111, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; Dacarbazine; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Glioblastoma; Humans; Kaplan-Meier Estimate; Mibefradil; Mice; Neoplasm Transplantation; Skin Neoplasms; Temozolomide; Time Factors; Xenograft Model Antitumor Assays

2013
Inhibition of glioblastoma and enhancement of survival via the use of mibefradil in conjunction with radiosurgery.
    Journal of neurosurgery, 2013, Volume: 118, Issue:4

    Topics: Animals; Brain Neoplasms; Calcium Channel Blockers; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Glioblastoma; Magnetic Resonance Imaging; Mibefradil; Proportional Hazards Models; Radiosurgery; Rats; Rats, Sprague-Dawley; Retrospective Studies; Survival Rate; Treatment Outcome

2013
Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells.
    Biochemical pharmacology, 2013, Apr-01, Volume: 85, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Brain Neoplasms; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Line, Tumor; Cell Survival; Glioblastoma; Humans; Mechanistic Target of Rapamycin Complex 2; Mibefradil; Multiprotein Complexes; Phosphorylation; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases

2013